A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This is a very early study looking at a new medicine, PF-08046049/SGN-BB228, for people with advanced melanoma and other solid cancers such as bowel, lung, pancreatic cancer, and mesothelioma. It's called a Phase 1 study, which means it's the first time this drug is being given to people. The main goals are to check if the drug is safe, what side effects it might have, and how it behaves in the body. Researchers also want to find the best dose to use in future studies. This research could help doctors understand if this new drug has the potential to become a treatment option for these types of cancers.
Auf einen Blick
Worum geht es in dieser Studie?
This study is investigating a new potential cancer medicine known by its research name, PF-08046049/SGN-BB228. It's being tested in people who have advanced melanoma, which is a type of skin cancer, and other solid tumour cancers, including those affecting the pancreas, bowel (colorectal cancer), lungs (non-small cell lung cancer), and a rare cancer called mesothelioma.
This is a 'Phase 1' study, which is the very first step in testing a new drug in humans. The main purpose of this phase is not to cure cancer, but to carefully check the drug's safety, understand how the body handles it, and identify any side effects. Researchers will also be looking for the highest dose that can be given safely to patients. Think of it like taking the first few careful steps with a new medicine; it's about making sure it's safe to use before exploring how effective it might be.
By taking part, individuals contribute vital information that helps researchers decide if this new drug is promising enough to move on to larger studies. This kind of early research is crucial for developing new cancer treatments in the future, potentially offering new options where existing treatments might no longer be working.
Wichtige Erkenntnisse
- This is an early-stage study for a new cancer drug.
- It's testing safety and how the drug works, not primarily aiming for a cure.
- It's for specific advanced cancers like melanoma, bowel, lung, and pancreatic cancer.
- Participation involves regular hospital visits for tests and medication.
- Potential for benefit and known risks of side effects will be discussed.
- Sie können jederzeit von der Studie zurücktreten.
Wer könnte berechtigt sein?
To be able to join this study, you generally need to be at least 18 years old. The study is open to both men and women.
Because this is a study for people with advanced cancer, you would need to have been diagnosed with one of the specific cancers being investigated, such as advanced melanoma, pancreatic cancer, bowel cancer, lung cancer (non-small cell type), or mesothelioma. Your doctors would need to confirm that your cancer fits the study's requirements.
There will also be other medical checks and criteria that your doctor will review to make sure this study is safe and appropriate for you. These might include your general health, how well your organs are working, and whether you've had certain treatments before. It's important to discuss all your medical history with the study team.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Do you have advanced melanoma, pancreatic, bowel, lung (non-small cell), or mesothelioma cancer?
- Are you generally well enough to take part in a study?
- Are you able to attend regular hospital visits?
- Are you willing to follow the study's rules and schedules?
Was beinhaltet die Teilnahme?
Taking part in this study would involve regular visits to the hospital or clinic. During these visits, you would have various assessments. These typically include physical examinations, blood tests and possibly urine tests, and scans (like CT scans) to monitor your health and how the treatment might be affecting your cancer. You would also be given the study medication, PF-08046049/SGN-BB228, which might be given as an infusion or in another form, depending on how the drug is designed. The study team will carefully explain the schedule for your medication.
Beyond these regular visits, there would also be follow-up appointments after you stop taking the study drug, to continue monitoring your health and any long-term effects. The total duration of your participation would vary depending on how you respond to the treatment and the specific study plan, but Phase 1 studies often involve a period of active treatment followed by monitoring.
Potenzielle Risiken und Vorteile
Standorte (3)
- —UnbestätigtFrankreich
- —UnbestätigtItalien
- —UnbestätigtDeutschland
Häufige Fragen
Was ist eine 'Phase 1'-Studie?
A Phase 1 study is the very first time a new drug is given to people. It mainly checks if the drug is safe, what dose to use, and if it has any side effects.
Will this drug cure my cancer?
The goal of this early study is not to cure cancer, but to understand if the drug is safe and how it works. It's a first step in developing new treatments.
What cancers does this study include?
It includes advanced melanoma, pancreatic, bowel, and lung cancer (non-small cell type), and mesothelioma.
Will I have to pay to join the study?
No, you will not have to pay for the study drug or any study-related medical care.
Kann ich die Studie jederzeit verlassen?
Yes, you can choose to leave the study at any point, and your decision will not affect your usual medical care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.